.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Chinese Patent Office
Medtronic
Novartis
Moodys
US Department of Justice
Federal Trade Commission
Johnson and Johnson
Deloitte

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,676,929

« Back to Dashboard

Which drugs does patent 6,676,929 protect, and when does it expire?


Patent 6,676,929 protects ABLAVAR and is included in one NDA.

This patent has forty-one patent family members in twenty-six countries.

Summary for Patent: 6,676,929

Title: Diagnostic imaging contrast agents with extended blood retention
Abstract:The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
Inventor(s): McMurry; Thomas J. (Winchester, MA), Sijiki; Hironao (Gifu, JP), Scott; Daniel M. (Acton, MA), Lauffer; Randall B. (Brookline, MA)
Assignee: Epix Medical, Inc. (Cambridge, MA)
Application Number:10/034,522
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Lantheus MedclABLAVARgadofosveset trisodiumSOLUTION;INTRAVENOUS021711-001Dec 22, 2008DISCNNoNo► Subscribe► Subscribe► SubscribeY
Lantheus MedclABLAVARgadofosveset trisodiumSOLUTION;INTRAVENOUS021711-002Dec 22, 2008DISCNNoNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,676,929

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,815Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,017,105Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,394,356Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,229,606Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,060,250Diagnostic imaging contrast agents with extended blood retention► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,676,929

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101011586► Subscribe
Germany69636635► Subscribe
Japan4064458► Subscribe
JapanH10513445► Subscribe
Iceland2505► Subscribe
Iceland4523► Subscribe
Israel116847► Subscribe
Hong Kong1078468► Subscribe
Hong Kong1002551► Subscribe
Finland973183► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Baxter
Colorcon
Moodys
Teva
Chinese Patent Office
AstraZeneca
Daiichi Sankyo
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot